Price movement over the last 24 hours
Align Technology, Inc. vs Hims and Hers Health Inc — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Hims and Hers Health Inc trades at $34.04 (market cap $7.96B). The key difference: Align Technology, Inc. is the larger of the two by market cap, and Align Technology, Inc. is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | HIMS | |
|---|---|---|
Market Cap | $12.86B | $7.96B |
Sector | Health | Health |
52-Week High | $207.19 | $66.18 |
52-Week Low | $124.88 | $14.52 |
Enterprise Value | $11.92B | $8.34B |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
Hims & Hers Health trades at $34.38, down 3.02% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights expansion in weight-loss therapies and a $400 million JPMorgan facility for financial flexibility, as the stock recovers from earlier regulatory concerns.
The outlook is cautiously optimistic, driven by growth in GLP-1 products and international expansion, but high valuation ratios and projected 2026 losses pose risks. Analyst consensus is a 'Hold' with a $33.57 price target, suggesting limited near-term upside from current levels amid competitive and execution challenges.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →